ECM
SEEL

ExodusPoint Capital Management’s Seelos Therapeutics, Inc. Common Stock SEEL Stock Holding History

ExodusPoint Capital Management’s Portfolio SEEL Stock Details SEEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-8
Closed -$70K – 2702
2021
Q3 		$70K Sell
8
-8
-50% -$68.8K ﹤0.01% 1943
2021
Q2 		$166K Buy
+16
New +$263K ﹤0.01% 2038

Other funds holding SEEL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
GJL
Gendell Jeffrey L $7.34B AUM 183.72% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UIC
Uniplan Investment Counsel Milwaukee, Wisconsin $974M AUM 21.37% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

ExodusPoint Capital Management's SEEL Position: Q4 2021 in Review

ExodusPoint Capital Management sold out of Seelos Therapeutics, Inc. Common Stock (SEEL) in Q4 2021, closing a stake of 8 shares — an estimated $70K sold.

ExodusPoint Capital Management first reported a position in SEEL in Q2 2021 and held it in 2 quarters. The position peaked at $166K in Q2 2021. 82 funds tracked by Wall St. Rank hold SEEL as of Q4 2021.

  • ExodusPoint Capital Management reported no remaining Seelos Therapeutics, Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
  • ExodusPoint Capital Management sold 8 Seelos Therapeutics, Inc. Common Stock shares in Q4 2021, an estimated $70K.
  • ExodusPoint Capital Management first reported a position in Seelos Therapeutics, Inc. Common Stock in Q2 2021 and held it in 2 quarters.
  • ExodusPoint Capital Management's Seelos Therapeutics, Inc. Common Stock position peaked at $166K in Q2 2021.
  • 82 funds tracked by Wall St. Rank held Seelos Therapeutics, Inc. Common Stock as of Q4 2021.

Based on ExodusPoint Capital Management's 13F filing for Q4 2021, filed 11 Feb 2022.